Porton PharmaTech, d.o.o.

SHARE

Porton & Pliant Joint Publication in ACS Catalysis Porton & Pliant Joint Publication in ACS Catalysis
03.04.2026

Porton & Pliant Joint Publication in ACS Catalysis

Recently, Dr. Jacob Y. Cha*, together with the Porton team, including Ziqing Zuo, William B. Reid, and Dr. Thorsten Rosner, has published a research article titled "Ru-Catalyzed Reductive Dehydration of Amides to Enamines: Catalyst-Loading-Controlled Selectivity" in ACS Catalysis, the American Chemical Society journal.

This peer-reviewed journal focuses on innovative catalysis methodologies and theoretical studies related to the synthesis and properties of high-value molecules, macromolecules, and advanced materials.

Porton's publication in ACS Catalysis marks another significant breakthrough, supported by the company's strong R&D capabilities and metal catalysis technology platform. It further demonstrates Porton's core expertise in catalytic technology innovation and process development.

Porton & Pliant Joint Publication in ACS Catalysis
Figure 1. Paper Abstract

Enamine compounds are valuable building blocks in organic synthesis and can participate in various transformations including regioselective alkylations, acylations, annulation cascades, cycloadditions and other heterocycle forming processes. Furthermore, enamines can be readily converted to the corresponding amines through direct reduction, which constitutes an important transformation in the pharmaceutical industry. The general method for enamine synthesis is typically achieved through the condensation of a secondary amine with a carbonyl compound under Lewis or Brønsted acid catalysis conditions. Other notable methods include transition metal catalyzed cross-coupling between vinyl halides and amines, dehydrogenation of alkyl amines, and hydroamination of alkynes. Despite these advances, most of these methods require harsh reaction conditions and/or are limited to ketone-derived enamines. As such, there is a paucity of examples describing the preparation of aldehyde-derived enamines. Conditions for aldenamine preparation typically employ strong Lewis acid catalysis or high temperatures and generally require stoichiometric dehydrating reagents or extended reaction times, significantly narrowing the scope.

In this publication, Jacob Y. Cha and the Porton team highlight findings that a single catalytic system can be tuned such that it switches between partial and complete amide reduction. Traditionally, selective amide reduction typically necessitates changes in catalyst structure, additives, or overall reaction conditions. However, in this publication they report a fundamentally different approach in which the chemoselectivity for enamines is governed solely by catalyst loading. At low Ru3(CO)12 loadings, enamine formation is strongly favored, whereas higher catalyst loadings promote complete reduction to amines. Once formed, the enamine remained chemically inert, avoiding overreduction to the amine, even with increased catalyst loadings that would have allowed direct reduction of the amide to the amine. This observation proved that the enamine was not merely an intermediate en route to the fully reduced amine.

The team hypothesized that loading-dependent divergence in reactivity reveals the existence of two distinct catalytic regimes within a single catalytic system. A series of experimental and computational studies highlighted that the enamine and amine products are both formed from a common iminium ion intermediate, however the enamine does not serve as a direct intermediate for the reduction to the amine, but rather an off-cycle byproduct.

Porton & Pliant Joint Publication in ACS Catalysis
Figure 2. Reductions of Enamine and Imine

DFT calculations supported evaluated relative stabilities of enamines/imines and their corresponding selectivity in E/Z enamine selectivity as well as their isomerization via an iminium intermediate which provide solid insights into the reaction mechanism. Thus, once the iminium ion is formed, under low catalyst loading, the combination of low steady-state iminium concentration and limited catalytic turnover kinetically suppresses over-reduction, enabling stable enamine formation. Higher catalyst loadings facilitate reduction of the iminium intermediate, furnishing the amine as the major product. Additional experiments found that mildly acid species like TMSOH can facilitate the equilibrium of enamine towards its iminium tautomer, which can undergo further reduction to the amine.

Porton & Pliant Joint Publication in ACS Catalysis
Figure 3. Proposed Reaction Mechanism

The selective reduction of amides to the corresponding enamines with high selectivity was demonstrated for a wide range of substrates.

Porton & Pliant Joint Publication in ACS Catalysis
Figure 4. Substrate Scope of Amides to Enamines

Porton offers agnostic and in-depth mechanistic work, involving both experimental, kinetic and computational studies, in support of Porton J-STAR projects at the request of clients. The successful publication not only showcases Porton's professional expertise in catalytic technology innovation but also validates the company's end-to-end technical advantages from R&D to production.

As a global leading CDMO, Porton has established multiple advanced technology platforms including metal catalysis, biocatalysis, flow chemistry, and photochemistry/electrochemistry, actively exploring and promoting the industrial application of green chemistry technologies in pharmaceutical manufacturing.

In the future, Porton will continue to help clients break through key bottlenecks through innovative and reliable CMC solutions, enabling earlier access to good medicines.

SHARE

Porton & Pliant Joint Publication in ACS Catalysis Porton & Pliant Joint Publication in ACS Catalysis
Porton & Pliant Joint Publication in ACS Catalysis Porton and Jianxiang Forge Strategic Partnership to Build a New High Ground for Large-scale Peptide Drug Manufacturing Porton Nominated for the 2025 Sedex Supply Chain Award Porton to Showcase Integrated CDMO Expertise at CPHI Frankfurt 2025 Porton Participates in Publishing an OPRD Paper, Demonstrating Strength in Drug Synthesis Technology Porton and Repare Therapeutics Collaborate on OPRD Publication, Demonstrating Strength in Synthetic Process Development and Optimization Porton Announces 2030 Sustainability Targets on World Environment Day Porton Awarded Gold Medal by EcoVadis, Ranked Among the Top 5% Globally Porton Pharma Solutions Celebrates 20 Years of Excellence and Innovation Porton to Showcase Integrated CDMO Expertise at BOS Basel 2025 Join Us at Chemspec Europe 2025 in June Porton's Near-Term Target Validated by the SBTi Porton Wins Outsourced Pharma 2025 CDMO Leadership Award Porton to Showcase Cutting-edge Innovations at BIO-Europe Spring 2025 Join Porton at Leading Industry Conferences to Explore Innovations and Network with Experts Porton Has Been Invited to the China–Slovenia Business and Investment Forum and Had a Friendly Meeting with Slovenian Officials. Porton’s New Modality Capacity Upgrade Ceremony Successfully Held Milestone | Comprehensive Enhancement of GMP Manufacturing Capacity and New Modality Service Capabilities at Porton Fengxian, Shanghai Porton Pharma Solutions Signed Strategic Partnership with Shanghai InnoStar Driving innovation and excellence in the CDMO industry, Porton Pharma Solutions 2024 CPHI Europe Review Technical Enability | Porton’s Team of Global Chemical Engineering and Technology Published Breakthrough Results in Crystal Growth & Design and reported them at the 2024 Crystal Engineering Gordon Research Conference Keep hope alive! We invite you to stay tuned to DMD Porton Experts Invited To Participate In The University Of Perugia Master PRO-API Program, Aiding In The Training Of Green Process Chemistry Professionals Porton Will Be Participating In Biotech Outsourcing Strategies Events This June Proton At CPhI North America Again Porton 2023 ESG Report Upcoming Porton Shows In Europe And The USA:Shaping Our Future Together Porton Makes Debut At DCAT Week 2024 To Jointly Promote Industry Development Join Our Founder And CEO @ DCAT Week Porton Pharma Solutions Joined The SBTi To Drive Climate Action Farewell To 2023, And WE Are Sailing Forward To 2024 The Pharma Crystallization Summit (PCS) Is Held Annually To Bring Together Developers Of New Medicines With Crystallization Challenges And The Crystallization Experts (Solution Providers) In The Industry And Academia. Porton Gets Improved In The 2023 S&P Global ESG Score Porton Pharma Solutions Announces New Flagship Facility Offering Integrated API Crystallization And Drug Product Development Services Pharma Digital Intelligence Summit Will Be Held On 5th, September, 2023 [Important Notice] Porton Announcement Regarding The Change Of Email Domain Porton Unveils Its Small Molecule Platform Headquarters In Shanghai PORTON Starts Construction Of Its Facility For Antibodies And ADCs In Shanghai Porton At DCAT Week 2023: A Highly Successful And Strategic Event Porton Released 2022 CSR Report Porton Delivers Strong 2022 Performance With 127% Sales Growth Porton Gets Above-Average S&P Global Environmental, Social, And Governance (ESG) Score
News

Insights Unveiled: Delve into Our Global News Hub!

22.05.2024

Porton Pharma Solutions embark on the next frontier in Mengeš, Slovenia

  • Opening ceremony of the state-of-the-art research and development laboratories for active pharmaceutical ingredients, small molecules, of Porton in Mengeš

  • A donation of EUR 20,000.00 to the municipality of Mengeš for the restoration of a flooded kindergarten

  • New jobs and further growth in the field of API's small molecules in Slovenia, Mengeš

Read the news

Cookie settings

Your current status

Show details